IMCR News and Press, Immunocore Holdings plc From 03/01/23

Immunocore Reports 2022 Financial Results and Provides Business Update KIMMTRAK / tebentafusp net revenues of £ 42 million ($ 51 million) in Q4 2022 and £ 117 million ($ 141 million) in 2022 ; approved in ov...

Summary Immunocore Holdings has strong, incremental sales and financials, a positive outlook. Total market dominance ensures demand for its products. IMCR stock is trading at an attractive valuation. Thesis Over the past year, Immunocore Holdings' (IMCR) stock price ha...

Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 23 February, 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pi...

Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV Data from the single ascending dose part of the Phase 1 trial shows IMC-M113V ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips In recent weeks, the Street has become much more enamored with pharma stocks than it was previously. The iShares Biotechnology ETF (NASDAQ: IBB ) climbed 6% so far this year. As a result, those who invest in pharma stocks...

Immunocore ( NASDAQ: IMCR ) reported preliminary total net product and net pre-product revenue (net sales) of eye cancer drug Kimmtrak (tebentafusp-tebn) and tebentafusp of about $50M in Q4, rising +25% Q/Q. For full year 2022, preliminary total net sales ...

Immunocore announces strategic priorities including pipeline expansion for 2023 - 2024 KIMMTRAK (tebentafusp-tebn) approv ed in over 30 countries with continued global expansion in 2023-2024 ; preliminary unaudited net sales of ...

Summary IDEAYA caught a bid in the back end of FY22' as investors began to take notice of advancements in its clinical pipeline. The rally seems to have flattened into the new year, so we wanted to check if there's scope for it to extend further. The company's investigational compou...

Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...

Immunocore to present at the 41 st Annual J . P . Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 04 January 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company ...